Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson's (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share. Tremfya ...

Janssen has debuted the first safety and efficacy data on Tremfya in ulcerative colitis, and so far, prospects for a label expansion look good. The readout accompanies positive 48-week results in ...

Tremfya is a biologic medication administered via injections into a vein or under the skin to treat plaque psoriasis. It works by blocking interleukin-23, a protein involved in the overactive immune ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.

Before you start treatment with Tremfya, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help ...

Tremfya is used to treat irritable bowel disease (ulcerative colitis and Crohn’s disease) in adults. It’s also approved for plaque psoriasis and psoriatic arthritis in adults and some children.